Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Protein synthesis in Plasmodium, the causative agent of malaria, is a fundamental process essential for parasite survival. It involves translating genetic information into proteins using ribosomes and associated factors. Unique features compared to human protein synthesis make it an attractive antimalarial drug target. The process is regulated at multiple levels, including global and mRNA-specific mechanisms. Components such as ribosomes and aminoacyl-tRNA synthetases are validated drug targets. Drugs like doxycycline inhibit translation, and novel compounds selectively inhibit Plasmodium protein synthesis.
Inhibition of ribosomal function; Inhibition of aminoacyl-tRNA synthetases; Disruption of elongation factors
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Protein Synthesis in Plasmodium.